Report On Honey Motivated To Malign Image Of Market Leader, Says Dabur
Dabur India Ltd. rejected the reports about the presence of cancer-causing substance in its honey and termed the claims as "motivated" and "baseless."
A high concentration of carcinogenic material was allegedly found in the popular brand Dabur Honey, according to a Zee News report. The samples of Dabur Honey were tested at the Centre for Analysis and Learning in Livestock and Food at the National Dairy Development Board in Gujarat.
"We stand by the purity of Dabur Honey," Chief Executive Officer Mohit Malhotra said during a post-earnings conference call on Thursday. "Every single batch of Dabur Honey dispatched from our factories complies with all FSSAI parameters, including HMF."
"In fact, Dabur Honey is the only leading honey brand in the country which has been granted the Agmark special certification post inspection and proper due diligence," he said. "This certifies the purity of Dabur Honey. We are also the only Indian honey brand that is packed in (the) U.S. FDA certified facilities."
Outside India, Dabur has a manufacturing presence in eight locations, and its products are sold in over 120 countries across the globe. "We conform with regulations of every country in the world, and there has not been any question of impurity," Malhotra said.
Honey products contribute 6–7% to Dabur's revenue in India and 5% to consolidated revenue, Abneesh Roy of Nuvama Wealth Management said in a note. He doesn't expect a big impact on honey sales over the longer term, but there could be a "small" impact in the short term.
This is not the first time that Dabur's honey has found itself embroiled in controversy for failing to pass quality tests. In 2020, the Centre for Science and Environment claimed that honey sold by 13 brands in India, including Dabur, had been found adulterated with sugar syrup.
The environment watchdog had at that time said that Dabur Honey flunked the stringent nuclear magnetic resonance test, considered the global gold standard for honey, as part of an investigation. Dabur, however, rejected the findings even then, saying that it was the only company in the country to have NMR testing equipment in its own laboratory.
The NMR tests have been made mandatory in India for honey that is meant for export as of Aug. 1, 2020.
The Food Safety and Standards Authority of India also started a pan-nation drive in 2021 to collect samples of honey and get them tested for adulteration. Queries emailed to the FSSAI remained unanswered till the time of publishing.
"There are about 65 parameters set by India's food regulator, and Dabur complies with all of them," Malhotra said. "So, the report is simply motivated to malign the image of the market leader."
Malhotra highlighted that Dabur gained 500 basis points of market share since the controversy happened last time because of the CSE report, which is a "clear indication that Dabur remains a strong player".
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.